adesso (ADN1) Q1 2025 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 TU earnings summary
9 Jul, 2026Executive summary
Achieved 11% organic sales growth to EUR 353.4 million in Q1 2025, outperforming peers in a challenging macroeconomic environment.
Maintained a workforce of over 10,400, with a 5–6% year-over-year increase and low attrition rate (~8%), supporting operational scalability.
EBITDA was EUR 17.8 million, flat year-over-year, with margin subdued by higher personnel and material costs.
Consolidated earnings for Q1 2025 were negative at EUR -4.1 million, down from EUR -3.3 million in Q1 2024, mainly due to increased depreciation and financial expenses.
Focused on IT services (90% of sales) and industry-specific solutions, with a diversified portfolio across insurance, banking, health, public, automotive, manufacturing, retail, and utilities.
Financial highlights
Revenue rose 11% year-over-year to EUR 353.4 million, with 84% generated in Germany.
EBITDA margin declined to 5.1% from 5.6% year-over-year.
Earnings per share were EUR -0.54, down from EUR -0.49 in Q1 2024.
Net debt increased to EUR 110.6 million as of March 31, 2025, up from EUR 90.5 million a year earlier, mainly due to shareholding increases and share buybacks.
Free cash flow and operating cash flow were negative in Q1 2025, reflecting higher investments, working capital, and typical seasonal patterns.
Outlook and guidance
Guidance for 2025 confirmed: revenue EUR 1.35–1.45 billion, EBITDA EUR 105–125 million.
Majority of earnings expected in H2 2025 due to more working days and anticipated pick-up in insurance and public sector business.
Expect improved margins in H2 due to higher utilization, reduced investments, and SAP offering.
Anticipate positive impact from increased government spending and digital transformation demand.
EBITDA margin target set at 8%+ X, with current performance on track.
Latest events from adesso
- Sales and EBITDA grew 12% and 34% in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 20258 Jul 2026 - 14% sales growth and margin gains in 2024 set the stage for further expansion in 2025.ADN1
H2 20248 Jul 2026 - Sales up 16% to €631.1m, but negative EPS and EBITDA guidance cut amid margin pressure.ADN1
H1 20248 Jul 2026 - Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 202611 May 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 202531 Mar 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025